Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours

por Pan, Y, Xu, R, Peach, M, Huang, C-P, Branstetter, D, Novotny, W, Herbst, R S, Eckhardt, S G, Holland, P M
Publicado 2011